Mark W. Verrill

Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Age, patient experience and satisfaction with breast cancer care: a cohort study using linked national cancer patient experience survey and cancer registry data.

Age, patient experience and satisfaction with breast cancer care: a cohort study using linked national cancer patient experience survey and cancer registry data.

Journal: BMJ open

Published: May 14, 2026

Evaluating breast cancer surgery ascertainment in England's routine healthcare data: A retrospective cohort study.

Evaluating breast cancer surgery ascertainment in England's routine healthcare data: A retrospective cohort study.

Journal: Cancer epidemiology

Published: April 14, 2026

The National Audit of Metastatic Breast Cancer (NAoMe): Sharing Key Findings and Recommendations From the 2025 State of the Nation Report.

The National Audit of Metastatic Breast Cancer (NAoMe): Sharing Key Findings and Recommendations From the 2025 State of the Nation Report.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: January 05, 2026

Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges.

Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges.

Journal: Future oncology (London, England)

Published: November 06, 2025

Clinicopathological, multimodal treatment, and survival patterns for men with breast cancer in England and Wales: a population-based cohort study.

Clinicopathological, multimodal treatment, and survival patterns for men with breast cancer in England and Wales: a population-based cohort study.

Journal: EClinicalMedicine

Published: October 06, 2025

Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour.

Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour.

Journal: NPJ breast cancer

Published: September 03, 2025

Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour.

Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour.

Journal: NPJ breast cancer

Published: September 03, 2025

Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial.

Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial.

Journal: JACC. CardioOncology

Published: May 01, 2024

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.

Journal: The Lancet. Oncology

Published: May 26, 2023

A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.

A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.

Journal: British journal of cancer

Published: May 05, 2023

Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT).

Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT).

Journal: BMJ open

Published: December 30, 2022

A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.

A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.

Journal: British journal of cancer

Published: November 14, 2022

Showing 1-12 of 29

Last Updated: 09/26/2026